Home Companies Catalysts Deep Dives
Kisqali ribociclib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2017-03-13
US LOE2029-08-01
Peak Sales Est$5000M
Formulations[{"id":"kisqali-oral","doses":"200mg tablets","route":"Oral","setting":"PATIENT_SELF","frequency":"D
Companies
NVS (ORIGINATOR)100%
Mechanism: CDK4/6 inhibitor
Expert: Selective inhibitor of cyclin-dependent kinases 4 and 6, inducing G1 cell cycle arrest in Rb-positive tumor cells. Continuous dosing maintains sustained target inhibition.
Everyday: Blocks proteins that help cancer cells divide, slowing tumor growth in hormone-receptor positive breast cancer.
Targets: ["CDK4/6"]
Revenue History
PeriodRevenue ($M)
2024$3,350M
2025$4,200M
Q4 2024$920M
Q4 2025$1,150M
Programs (2)
IndicationStageKey StudyRegional Status
HR+/HER2- mBCAPPROVEDMONALEESA-2/3/7[{"stage":"APPROVED","region":"US","approval_date":"2017-03"}]
HR+/HER2- early BCAPPROVEDNATALEE[{"stage":"APPROVED","region":"US","approval_date":"2024-09"}]
Notes
CDK4/6 inhibitor. OS advantage in HR+/HER2- breast cancer. Growing rapidly.
Data from Supabase · Updated 2026-03-24